Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$92.60
▼ $1.15 (-1.2%)
Market data updated: 09/17 10:25 AM
Fundamentals updated: 09/16/2026
News analyzed: 09/17/2026
Market Cap
$118.45B
Day Range
$92.42 - $94.55
52-Week Range
$73.31 - $106.33
Beta
—
Next Earnings
16.11.2026
MDT is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-0.1% (1Y)
Strengths: 14/32 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Operating margin stability
Operating margin is stable or improving over time
Quality
Biggest negative driver
DCF Fair Value
Estimated fair value: $70.81 vs. price $92.60 (-23.5%)
Fair Value
What to watch next
When today echoes the past.
83/100
Similarity
15
Historical Matches
90/100
Analog Quality
+1.3%
Median 40D Outcome
81/100
Pattern Consistency
🟢 Bullish
40%
+2.5% … +5.5%
🟡 Base
27%
-0.2% … +0.7%
🔴 Bearish
33%
-3.7% … -1.7%
Typical timeframe (based on real historical rates clearing a 60% bar): 60 trading days.
📌 Bottom line: Out of 15 similar historical cases for this stock, 40% (95% CI 20%–64%) saw the stock rise within 20 trading days, with a median gain of +0.6%.
Echo #1 — Trend Acceleration
11 occurrence(s) · 45% historical success
Historical outcome rate is not a probability — it's what happened in this specific historical sample, with a 95% confidence range.
| Horizon | Positive rate (95% CI) | Median | 25th–75th pct | Baseline median |
|---|---|---|---|---|
| 5D | 27% (11%–52%) | -0.9% | -2.3% … +0.9% | +0.1% |
| 10D | 33% (15%–58%) | +0.0% | -0.8% … +1.9% | +0.2% |
| 20D | 40% (20%–64%) | +0.6% | -1.4% … +2.9% | +0.6% |
| 40D | 53% (30%–75%) | +1.3% | -1.7% … +4.6% | +0.8% |
| 60D | 67% (42%–85%) | +3.3% | -6.1% … +6.8% | +1.7% |
Sample size: 15 analogs, each at least 10 trading days apart (no double-counted overlapping events).
What happened after each historical match (20-day return)
| Date | Similarity | Regime | 20D outcome | 60D outcome |
|---|---|---|---|---|
| 2020-09-15 | 83/100 | Uptrend | -0.6% | +5.0% |
| 2021-01-05 | 79/100 | Uptrend | -3.7% | +1.1% |
| 2018-06-04 | 78/100 | Uptrend | -1.7% | +9.4% |
| 2020-12-16 | 77/100 | Uptrend | +1.6% | +3.5% |
| 2024-09-16 | 75/100 | Uptrend | -0.1% | -7.2% |
| 2024-09-30 | 75/100 | Uptrend | +0.6% | -9.4% |
| 2024-01-04 | 75/100 | Uptrend | +4.4% | +1.5% |
| 2020-08-18 | 75/100 | Consolidation | +5.8% | +8.5% |
| 2021-03-15 | 74/100 | Consolidation | +3.8% | +3.3% |
| 2020-10-23 | 74/100 | Uptrend | -1.1% | +5.8% |
| 2025-02-13 | 74/100 | Uptrend | +0.9% | -6.9% |
| 2024-08-14 | 74/100 | Consolidation | +10.1% | +7.8% |
| 2025-09-02 | 74/100 | Uptrend | +2.0% | +12.9% |
| 2024-02-01 | 73/100 | Uptrend | -5.1% | -8.2% |
| 2024-10-16 | 73/100 | Uptrend | -2.2% | -5.3% |
Every accepted match is compared to today across 6 domains (price structure, momentum, technical, volatility, volume, relative strength) using z-scored feature distances — no single indicator dominates. Matches within 10 trading days of each other count as one event, not independent evidence. Outcome rates use a Wilson confidence interval (never a raw percentage alone), the mean return is winsorized against extreme outliers, and "Analog Quality" separately captures sample size, data completeness, and regime match — distinct from raw similarity. Relative strength is measured against SPY and against XLV (this stock's sector).
Cross-stock analogs — real other companies, not this stock's own history.
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
59
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
58
Quality
63
Value
38
Momentum
65
Risk
54
Sentiment
62
Fundamental
67
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
SCANNING MDT...
Recent media coverage of Medtronic highlights its financial performance and investor outlook. The company reported a **13.7% organic revenue growth** in Q1 2027, driven by its cardiovascular and surgical segments, while analysts discuss its **stronger growth and earnings potential** alongside lingering risks like margins, currency fluctuations, and execution challenges. Dividend-focused commentary also notes its **3.5% yield**, though sustainability concerns remain. No major operational or regulatory shifts were reported.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Medtronic. News trend score: 62. Reason: 7 of the last 20 articles are positive, versus 5 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
22
🎯 Conviction (vs. Emotion)
42
Psychology
72
Fundamentals
67
Technical
65
Valuation
38
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The price rise has far outpaced the actual improvement in fundamental data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+19%
Market Narrative
61
Fundamental Reality
42
Narrative Gap
+19
🧠 StockIQ Psychologist
The market’s dominant **herding** behavior reflects relative underperformance versus peers, consistent with traders aligning with broader sector weakness. Elevated **euphoria** and **overconfidence** scores—driven by extreme valuation gaps—suggest detached optimism, while **anchoring** near resistance hints at tactical positioning. The **narrative-reality gap** (31 points) implies traders may overestimate fundamentals. The key question: *Will peer weakness spill over, or will valuation disconnects sustain momentum?*
Updated: 09/09/2026, 12:12 PM
What could change this?
👥 What the crowd believes
"Medtronic (MDT) offers a 3.5% yield with strong profitability"
"Cardiovascular and surgical segments drove 13.7% organic revenue growth"
"margin, currency and execution risks keep investors selective"
📈 13D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Edgar Lawrence Smith — 79/100
🔴 Weakest match
Samuel Armstrong Nelson — 14/100
🗣️ Why do they disagree?
The methodologies split sharply on MDT, with the highest-scoring models—Edgar Lawrence Smith (79) and Walter Bagehot (76)—seeing it as a long-term hold or resilient credit, while the lowest—Peter Lynch (29) and Benjamin Graham (33)—dismiss it outright as lacking growth or value. Smith and Bagehot’s enthusiasm stems from its perceived stability and potential for decade-long compounding, contrasting sharply with Lynch’s and Graham’s focus on undervaluation or explosive growth, which MDT fails to meet. The middle ground, from Morgan Housel (65) to Howard Marks (46), suggests it’s a *possible* patient hold but not a slam dunk—some see quiet compounding potential, while others warn of overpriced expectations or late-cycle risks. Even within the same investor (Marks), the market-cycle lens slashes the score to 35, highlighting how context drastically alters verdicts.
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 79
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 76
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟢 71
Reasonable capital-preservation profile
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 69
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟢 67
The kind of quiet compounder a patient holder could actually stick with
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 59
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 55
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 51
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 51
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 47
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 43
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 38
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 33
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 29
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 14
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 300 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (7 bullish · 4 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
65.0%
Operating Margin
17.8%
Net Margin
13.2%
EBITDA Margin
25.9%
ROE
9.7%
ROA
5.2%
ROIC
—
EPS
$3.75
Cash
$1.95B
Total Debt
$1.79B
Current Ratio
2.13
Debt/Equity
0.04
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 26.6.2026 | $0.720 |
| 25.6.2026 | $0.720 |
| 27.3.2026 | $0.710 |
| 26.3.2026 | $0.710 |
| 26.12.2025 | $0.710 |
| 25.12.2025 | $0.710 |
| 26.9.2025 | $0.710 |
| 25.9.2025 | $0.710 |
| 27.6.2025 | $0.710 |
| 26.6.2025 | $0.710 |
| 28.3.2025 | $0.700 |
| 27.3.2025 | $0.700 |
How is Fair Value calculated? →
Current Price
$92.60
Estimated Fair Value (DCF)
$70.81
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-23.5%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
5.2%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 5.2% | $5.71B | $5.24B |
| 2 | 4.5% | $5.97B | $5.02B |
| 3 | 3.9% | $6.20B | $4.79B |
| 4 | 3.2% | $6.40B | $4.53B |
| 5 | 2.5% | $6.56B | $4.26B |
Base FCF (last actual year)
$5.43B
Terminal Value
$103.41B
Present Value of Terminal Value
$67.21B
Enterprise Value
$91.05B
Net Debt
$-161.00M
Equity Value
$91.22B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$38.40
Tangible Book Value per Share (Tangible NAV)
-$2.54
Sentiment based on basic keywords (not AI) — 7 positive, 8 neutral, 5 negative out of the last 20 articles.
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Benzinga · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
SeekingAlpha · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 14.9.2026
Yahoo · 14.9.2026
ChartMill · 14.9.2026
Yahoo · 14.9.2026
Yahoo · 14.9.2026
Yahoo · 14.9.2026
Benzinga · 14.9.2026
24/7 Wall St. · 13.9.2026
Yahoo · 13.9.2026
Medtronic (MDT) currently has a StockIQ AI score of 59/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
MDT currently scores 59/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, MDT's estimated fair value is $70.81, which is 23.5% below the current price of $92.60. This is one valuation model among several signals in the fair-value category, not a price target.
MDT's technical score is 65/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Operating margin is stable or improving over time; Debt/equity: 0.04; Current ratio: 2.13.
Based on the real signals StockIQ computed: Estimated fair value: $70.81 vs. price $92.60 (-23.5%); Calmar: 0.15 (3y annualized return 4.4% / max drawdown 30.0%); MACD histogram is negative — falling momentum.
Yes — MDT has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Marinaro Michael | Tax Withholding in Shares | 20.8.2026 | 116,336 | -1,084 | $92.30 |
| Marinaro Michael | Tax Withholding in Shares | 20.8.2026 | 1,084 | -1,084 | $92.30 |
| Martha Geoffrey | Grant/Award from Employer | 3.8.2026 | 273,150 | +273,150 | — |
| Martha Geoffrey | Grant/Award from Employer | 3.8.2026 | 295,002 | +295,002 | — |
| Martha Geoffrey | Grant/Award from Employer | 3.8.2026 | 103,831 | +103,831 | — |
| Martha Geoffrey | Grant/Award from Employer | 3.8.2026 | 41,533 | +41,533 | — |
| KIIL HARRY SKIP | Grant/Award from Employer | 3.8.2026 | 65,556 | +65,556 | — |
| KIIL HARRY SKIP | Grant/Award from Employer | 3.8.2026 | 23,074 | +23,074 | — |
| KIIL HARRY SKIP | Grant/Award from Employer | 3.8.2026 | 9,230 | +9,230 | — |
| Marinaro Michael | Grant/Award from Employer | 3.8.2026 | 77,848 | +77,848 | — |
| Marinaro Michael | Grant/Award from Employer | 3.8.2026 | 27,400 | +27,400 | — |
| Marinaro Michael | Grant/Award from Employer | 3.8.2026 | 46,147 | +46,147 | — |
| Pieton Thierry | Grant/Award from Employer | 3.8.2026 | 81,945 | +81,945 | — |
| Marinaro Michael | Grant/Award from Employer | 3.8.2026 | 10,960 | +10,960 | — |
| Pieton Thierry | Grant/Award from Employer | 3.8.2026 | 28,842 | +28,842 | — |
| Pieton Thierry | Grant/Award from Employer | 3.8.2026 | 11,537 | +11,537 | — |
| Quinn Michelle | Grant/Award from Employer | 3.8.2026 | 45,070 | +45,070 | — |
| Quinn Michelle | Grant/Award from Employer | 3.8.2026 | 15,863 | +15,863 | — |
| Quinn Michelle | Grant/Award from Employer | 3.8.2026 | 6,346 | +6,346 | — |
| Thompson Kweli | Grant/Award from Employer | 3.8.2026 | 49,167 | +49,167 | — |
| Thompson Kweli | Grant/Award from Employer | 3.8.2026 | 17,306 | +17,306 | — |
| Thompson Kweli | Grant/Award from Employer | 3.8.2026 | 6,923 | +6,923 | — |
| Walter Matthew R. | Grant/Award from Employer | 3.8.2026 | 40,973 | +40,973 | — |
| Walter Matthew R. | Grant/Award from Employer | 3.8.2026 | 14,421 | +14,421 | — |
| Walter Matthew R. | Grant/Award from Employer | 3.8.2026 | 5,769 | +5,769 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
12,134,511 shares short as of 2026-08-31 · vs. 18,120,230 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
44.7% of trading volume this week was short selling, vs. 42.0% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology